Aktis Oncology, Inc. (AKTS) vs Bicara Therapeutics Inc. Common Stock (BCAX)
A side-by-side comparison of Aktis Oncology, Inc. and Bicara Therapeutics Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
BCAX
Bicara Therapeutics Inc. Common Stock
$17.29HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AKTS vs BCAX
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)BCAX -3.7% (-3.7%/yr)BCAX compounded faster over this window
AKTS BCAX
AKTS vs BCAX: by the numbers
- •BCAX is the larger company ($1.14B vs $989M market cap).
- •Both run net losses; BCAX's is the smaller (0.00% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | BCAX |
|---|---|---|
| P/S ratio | 98.32 | N/A |
| P/B ratio | 2.04 | 2.42 |
Profitability
| Metric | AKTS | BCAX |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1149.52% | 0.00% |
| Net margin | -727.04% | 0.00% |
| ROE | -15.09% | -39.54% |
| ROIC | -16.54% | -42.98% |
Go deeper
Dig into the metrics
Aktis Oncology ROEBicara Therapeutics Inc. Common Stock ROEAktis Oncology operating marginBicara Therapeutics Inc. Common Stock operating marginAktis Oncology revenue growthBicara Therapeutics Inc. Common Stock revenue growthAktis Oncology free cash flowBicara Therapeutics Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.